GlassScriptPhysician profile
Gwendoline Fang
NPI 1396062311
$1,596.41
in general payments reported to CMS, 2019-2025
24 companies · $474 in 2025
The $474 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $93.95 · 2021: $216 · 2022: $148 · 2023: $414 · 2024: $250 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.69 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.71 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $227.45 | 2021-2025 | |
| Astellas Pharma US INC | $195.97 | 2023-2025 | Veozah |
| Amgen INC. | $116.01 | 2021-2025 | Evenity, Prolia, Prolia |
| Channel Medsystems, INC. | $95.88 | 2023 | |
| Lilly USA, LLC | $93.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $78.64 | 2020-2023 | Vaxneuvance, Gardasil 9, Proquad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.19 | 2021-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $66.06 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $55.46 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $47.35 | 2024-2025 | Spravato |
| Hologic Sales and Service, LLC | $41.89 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.60 | 2021 | |
| Coopersurgical, INC. | $26.00 | 2020 | |
| Axsome Therapeutics, INC. | $23.64 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $23.58 | 2025 | Xyosted |
| Organon LLC | $22.24 | 2021 | |
| Sage Therapeutics, LLC | $21.11 | 2024 | |
| Exact Sciences Corporation | $17.84 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $16.91 | 2023 | Quviviq |
| Amarin Pharma, INC. | $15.73 | 2020 | |
| Meditrina | $14.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwendoline Fang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.